(Q51991624)

19 April 2018

title

Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. (English)

1 reference

19 April 2018

1 reference

1 reference

1 reference

Ebert U

1

1 reference

19 April 2018

Siepmann M

2

1 reference

19 April 2018

Oertel R

3

1 reference

19 April 2018

Wesnes KA

4

1 reference

19 April 2018

Kirch W

5

1 reference

19 April 2018

publication date

1 August 1998

1 reference

19 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

19 April 2018

volume

38

1 reference

19 April 2018

issue

8

1 reference

19 April 2018

page(s)

720-726

1 reference

19 April 2018

In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Cholinesterase Inhibition in the Scopolamine Model of Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Pharmacokinetics and oral bioavailability of scopolamine in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Human flash-VEP and quantitative EEG are independently affected by acute scopolamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

Frequency analysis of the resting awake EEG in mild senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1998.TB04812.X

10.1002/J.1552-4604.1998.TB04812.X

21 January 2018

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

9725548

1 reference

19 April 2018